THE GOG FOUNDATION, INC.
A HALF CENTURY OF TRANSFORMING
THE STANDARD OF CARE
The GOG Foundation, Inc.
A Half Century of Transforming the Standard of Care

Dedication:
This publication is dedicated to Larry J. Copeland, MD for his incredible leadership in serving as The GOG Foundation, Inc. President from 2017 - 2023

Copyright 2023 © by The GOG Foundation, Inc.
OUR MISSION

To conduct clinical and translational research that positively impacts patients through the prevention and treatment of gynecologic malignancies

OUR VISION

To be the premier collaborative network for transformative research in gynecologic malignancies
Originally known as the Gynecologic Oncology Group (GOG legacy), our history dates back to 1970, when a small group of gynecologic oncologists decided that there was a need to establish a clinical trials group. The GOG (legacy) was successful in acquiring a federal grant through the National Cancer Institute's (NCI) Cancer Therapy Evaluation Program (CTEP). The GOG (legacy) initially embraced the participation of medical oncologists, radiation oncologist, research nurses and clinical statisticians. The translational researchers were invited to enhance our clinical trial process in the early 1990's. Secondary to an NCI restructuring of the cancer clinical trial program, the GOG (legacy) transitioned from a Principal Investigator-led program to a corporation with a board of directors' governance, The GOG Foundation, Inc. (GOG). This will be explained in the Chapter outlining the history of the GOG.

Multiple GOG trials conducted through our legacy Gynecologic Oncology Group organization, our new federal grant organization - NRG Oncology - and our recent GOG Partners program have led to practice-changing clinical trials, as described later in this publication.

Our current corporation is The GOG Foundation, Inc. Under this umbrella function both the gynecologic oncology arm of NRG Oncology and the GOG Partners program conducts industry sponsored trials.

The current mission of the GOG Foundation, Inc., is to transform the standard of care for patients with gynecologic malignancies. Over the past 50 years, the GOG has been a major contributor to the current algorithms for the management of gynecologic cancers and the trials leading to these management pathways are highlighted in this publication.

But if it weren’t for the exceptional commitment of our clinical trialists and the participating researchers and patients throughout the country we would not have achieved the successes noted in this publication.

It is a humble honor to serve as President of this Foundation, as I know the core ingredient of the success of this program is the hard work and commitment of our gynecologic community. I know even greater achievements are in our future.

This is our story, and we hope that you enjoy it!

Larry J. Copeland, MD
President, The GOG Foundation, Inc.